USD10
RPRX Shares
About Royalty PharmaRoyalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
USD10
RPRX Shares
About Royalty PharmaRoyalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$25.79B
OPEN PRICE
$58.50
LOW (1Y)
$34.08
HIGH (1Y)
$58.84
LOW (24H)
$58.12
HIGH (24H)
$59.44
VOLUME (24H)
$2.54M
29.26%
Price history
Time | Price | Change |
|---|---|---|
Today | $58.50 | |
1 Day | $58.53 | |
1 Week | $56.21 | |
1 Month | $52.37 | |
1 Year | $35.65 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.